Skip to main content
Erschienen in: Clinical Rheumatology 6/2013

01.06.2013 | Original Article

NK cells dysfunction in systemic lupus erythematosus: relation to disease activity

verfasst von: Ana Henriques, Luís Teixeira, Luís Inês, Tiago Carvalheiro, Ana Gonçalves, António Martinho, Maria Luísa Pais, José António Pereira da Silva, Artur Paiva

Erschienen in: Clinical Rheumatology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Through their cytotoxic capacities and cytokine production, natural killer (NK) cells modulate autoimmune diseases. However, their role in the pathogenesis of systemic lupus erythematosus (SLE) has not been extensively studied. The aim of this study was to analyse the immunophenotypic and functional characteristics of the two major NK cell subsets in SLE and relate them with disease activity. Peripheral blood samples from 44 patients with active (n = 18) and inactive SLE (n = 26) and 30 controls were analysed by flow cytometry to evaluate NK cell subsets, according to: the differential expression of CXCR3 and CD57; expression of granzyme B and perforin; and production of interferon gamma (IFN-γ) and tumor necrosis alpha (TNF-α), after PMA/ionomycin activation. A clear decrease in absolute and relative numbers of circulating NK cells was found in SLE, particularly in active disease, while the proportions of the major NK cell subsets were unaffected. Active SLE was associated with a reduced CXCR3 expression on both NK cell subsets and a lower frequency of CD56dim NK cells expressing CXCR3. Furthermore, granzyme B expression was decreased in both SLE groups, but the percentage of NK cells expressing granzyme B and perforin was higher, particularly in active disease. We found a significant decrease in the percentage of CD56bright and CD56dim NK cells producing TNF-α and of its expression on CD56dim NK cells in active disease, while IFN-γ expression on CD56bright NK cells was increased in both SLE groups. Our findings suggest that NK cell subsets exhibit unique phenotypic and functional changes that are particularly evident in active SLE, and they may have the potential to affect the disease outcome.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ringold S, Lynm C, Golub RM (2011) JAMA patient page. Systemic lupus erythematosus. JAMA 306:668PubMedCrossRef Ringold S, Lynm C, Golub RM (2011) JAMA patient page. Systemic lupus erythematosus. JAMA 306:668PubMedCrossRef
2.
Zurück zum Zitat Mok CC, Lau CS (2003) Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56:481–490PubMedCrossRef Mok CC, Lau CS (2003) Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56:481–490PubMedCrossRef
3.
Zurück zum Zitat Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ (2000) Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 76:227–324PubMedCrossRef Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ (2000) Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 76:227–324PubMedCrossRef
4.
Zurück zum Zitat Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR (1998) Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 41:1241–1250PubMedCrossRef Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR (1998) Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 41:1241–1250PubMedCrossRef
5.
Zurück zum Zitat Gaipl US, Voll RE, Sheriff A, Franz S, Kalden JR, Herrmann M (2005) Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev 4:189–194PubMedCrossRef Gaipl US, Voll RE, Sheriff A, Franz S, Kalden JR, Herrmann M (2005) Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev 4:189–194PubMedCrossRef
6.
Zurück zum Zitat Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS (2003) Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48:2888–2897PubMedCrossRef Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS (2003) Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48:2888–2897PubMedCrossRef
8.
Zurück zum Zitat Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17:189–220PubMedCrossRef Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17:189–220PubMedCrossRef
9.
Zurück zum Zitat Seaman WE, Sleisenger M, Eriksson E, Koo GC (1987) Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol 138:4539–4544PubMed Seaman WE, Sleisenger M, Eriksson E, Koo GC (1987) Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol 138:4539–4544PubMed
10.
Zurück zum Zitat Raulet DH (2004) Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 5:996–1002PubMedCrossRef Raulet DH (2004) Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 5:996–1002PubMedCrossRef
11.
Zurück zum Zitat Horwitz DA, Gray JD, Ohtsuka K, Hirokawa M, Takahashi T (1997) The immunoregulatory effects of NK cells: the role of TGF-beta and implications for autoimmunity. Immunol Today 18:538–542PubMedCrossRef Horwitz DA, Gray JD, Ohtsuka K, Hirokawa M, Takahashi T (1997) The immunoregulatory effects of NK cells: the role of TGF-beta and implications for autoimmunity. Immunol Today 18:538–542PubMedCrossRef
12.
Zurück zum Zitat Park YW, Kee SJ, Cho YN et al (2009) Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 60:1753–1763PubMedCrossRef Park YW, Kee SJ, Cho YN et al (2009) Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 60:1753–1763PubMedCrossRef
13.
Zurück zum Zitat Schleinitz N, Vely F, Harle JR, Vivier E (2010) Natural killer cells in human autoimmune diseases. Immunology 131:451–458PubMedCrossRef Schleinitz N, Vely F, Harle JR, Vivier E (2010) Natural killer cells in human autoimmune diseases. Immunology 131:451–458PubMedCrossRef
14.
Zurück zum Zitat Yabuhara A, Yang FC, Nakazawa T et al (1996) A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 23:171–177PubMed Yabuhara A, Yang FC, Nakazawa T et al (1996) A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 23:171–177PubMed
15.
Zurück zum Zitat Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR (2005) Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 141:165–173PubMedCrossRef Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR (2005) Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 141:165–173PubMedCrossRef
16.
Zurück zum Zitat Hervier B, Beziat V, Haroche J et al (2011) Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-gamma production in patients with active disease. Arthritis Rheum 63:1698–1706PubMedCrossRef Hervier B, Beziat V, Haroche J et al (2011) Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-gamma production in patients with active disease. Arthritis Rheum 63:1698–1706PubMedCrossRef
17.
Zurück zum Zitat Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633–640PubMedCrossRef Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633–640PubMedCrossRef
18.
Zurück zum Zitat Sentman CL, Meadows SK, Wira CR, Eriksson M (2004) Recruitment of uterine NK cells: induction of CXC chemokine ligands 10 and 11 in human endometrium by estradiol and progesterone. J Immunol 173:6760–6766PubMed Sentman CL, Meadows SK, Wira CR, Eriksson M (2004) Recruitment of uterine NK cells: induction of CXC chemokine ligands 10 and 11 in human endometrium by estradiol and progesterone. J Immunol 173:6760–6766PubMed
19.
Zurück zum Zitat Proudfoot AE (2002) Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2:106–115PubMedCrossRef Proudfoot AE (2002) Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2:106–115PubMedCrossRef
20.
Zurück zum Zitat Lacotte S, Brun S, Muller S, Dumortier H (2009) CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 1173:310–317PubMedCrossRef Lacotte S, Brun S, Muller S, Dumortier H (2009) CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 1173:310–317PubMedCrossRef
21.
Zurück zum Zitat Yap DY, Lai KN (2010) Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol 2010:365083PubMedCrossRef Yap DY, Lai KN (2010) Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol 2010:365083PubMedCrossRef
22.
Zurück zum Zitat Avramescu C, Biciusca V, Daianu T et al (2010) Cytokine panel and histopathological aspects in the systemic lupus erythematosus. Rom J Morphol Embryol 51:633–640PubMed Avramescu C, Biciusca V, Daianu T et al (2010) Cytokine panel and histopathological aspects in the systemic lupus erythematosus. Rom J Morphol Embryol 51:633–640PubMed
23.
Zurück zum Zitat Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef
24.
Zurück zum Zitat Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291PubMed Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291PubMed
25.
Zurück zum Zitat Griffiths B, Mosca M, Gordon C (2005) Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19:685–708PubMedCrossRef Griffiths B, Mosca M, Gordon C (2005) Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19:685–708PubMedCrossRef
26.
Zurück zum Zitat Huang Z, Fu B, Zheng SG, Li X, Sun R, Tian Z, Wei H (2011) Involvement of CD226+ NK cells in immunopathogenesis of systemic lupus erythematosus. J Immunol 186:3421–3431PubMedCrossRef Huang Z, Fu B, Zheng SG, Li X, Sun R, Tian Z, Wei H (2011) Involvement of CD226+ NK cells in immunopathogenesis of systemic lupus erythematosus. J Immunol 186:3421–3431PubMedCrossRef
27.
Zurück zum Zitat Erkeller-Yuksel FM, Lydyard PM, Isenberg DA (1997) Lack of NK cells in lupus patients with renal involvement. Lupus 6:708–712PubMedCrossRef Erkeller-Yuksel FM, Lydyard PM, Isenberg DA (1997) Lack of NK cells in lupus patients with renal involvement. Lupus 6:708–712PubMedCrossRef
28.
Zurück zum Zitat Böhm I (2006) Quantification of absolute peripheral white blood cells and their subsets in patients with lupus erythematosus: comparison with other inflammatory diseases with and without autoimmune background. Biomed Pharmacother 60:92–95PubMedCrossRef Böhm I (2006) Quantification of absolute peripheral white blood cells and their subsets in patients with lupus erythematosus: comparison with other inflammatory diseases with and without autoimmune background. Biomed Pharmacother 60:92–95PubMedCrossRef
29.
Zurück zum Zitat Böhm I (2005) Nuclear-targeting autoantibodies induced nuclear PARP cleavage accompanied by more pronounced decrease of peripheral white blood cells than Ro/SSA and La/SSB antigen-targeting autoantibodies. J Clin Immunol 25:99–105PubMedCrossRef Böhm I (2005) Nuclear-targeting autoantibodies induced nuclear PARP cleavage accompanied by more pronounced decrease of peripheral white blood cells than Ro/SSA and La/SSB antigen-targeting autoantibodies. J Clin Immunol 25:99–105PubMedCrossRef
30.
Zurück zum Zitat Böhm I (2004) Apoptosis: the link between autoantibodies and leuko-/lymphocytopenia in patients with lupus erythematosus. Scand J Rheumatol 33:409–416PubMedCrossRef Böhm I (2004) Apoptosis: the link between autoantibodies and leuko-/lymphocytopenia in patients with lupus erythematosus. Scand J Rheumatol 33:409–416PubMedCrossRef
31.
Zurück zum Zitat Goto M, Tanimoto K, Horiuchi Y (1980) Natural cell mediated cytotoxicity in systemic lupus erythematosus: suppression by antilymphocyte antibody. Arthritis Rheum 23:1274–1281PubMedCrossRef Goto M, Tanimoto K, Horiuchi Y (1980) Natural cell mediated cytotoxicity in systemic lupus erythematosus: suppression by antilymphocyte antibody. Arthritis Rheum 23:1274–1281PubMedCrossRef
32.
Zurück zum Zitat Struyf NJ, Snoeck HW, Bridts CH, De Clerck LS, Stevens WJ (1990) Natural killer cell activity in Sjogren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes. Ann Rheum Dis 49:690–693PubMedCrossRef Struyf NJ, Snoeck HW, Bridts CH, De Clerck LS, Stevens WJ (1990) Natural killer cell activity in Sjogren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes. Ann Rheum Dis 49:690–693PubMedCrossRef
33.
Zurück zum Zitat Nagler A, Lanier LL, Cwirla S, Phillips JH (1989) Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 143:3183–3191PubMed Nagler A, Lanier LL, Cwirla S, Phillips JH (1989) Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 143:3183–3191PubMed
34.
Zurück zum Zitat Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF (1983) Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol 131:1789–1796PubMed Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF (1983) Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol 131:1789–1796PubMed
35.
Zurück zum Zitat Clark-Lewis I, Mattioli I, Gong JH, Loetscher P (2003) Structure–function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278:289–295PubMedCrossRef Clark-Lewis I, Mattioli I, Gong JH, Loetscher P (2003) Structure–function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278:289–295PubMedCrossRef
36.
Zurück zum Zitat Carvalheiro T, Rodrigues A, Lopes A, et al. (2012) Tolerogenic versus inflammatory activity of peripheral blood monocytes and dendritic cells subpopulations in systemic lupus erythematosus. Clin Dev Immunol 2012: 934161 Carvalheiro T, Rodrigues A, Lopes A, et al. (2012) Tolerogenic versus inflammatory activity of peripheral blood monocytes and dendritic cells subpopulations in systemic lupus erythematosus. Clin Dev Immunol 2012: 934161
37.
Zurück zum Zitat Henriques A, Ines L, Couto M et al (2010) Frequency and functional activity of Th17, Tc17 and other T-cell subsets in systemic lupus erythematosus. Cell Immunol 264:97–103PubMedCrossRef Henriques A, Ines L, Couto M et al (2010) Frequency and functional activity of Th17, Tc17 and other T-cell subsets in systemic lupus erythematosus. Cell Immunol 264:97–103PubMedCrossRef
38.
Zurück zum Zitat Henriques A, Ines L, Carvalheiro T et al (2011) Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus. Rheumatol Int 32:863–869PubMedCrossRef Henriques A, Ines L, Carvalheiro T et al (2011) Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus. Rheumatol Int 32:863–869PubMedCrossRef
Metadaten
Titel
NK cells dysfunction in systemic lupus erythematosus: relation to disease activity
verfasst von
Ana Henriques
Luís Teixeira
Luís Inês
Tiago Carvalheiro
Ana Gonçalves
António Martinho
Maria Luísa Pais
José António Pereira da Silva
Artur Paiva
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 6/2013
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-013-2176-8

Weitere Artikel der Ausgabe 6/2013

Clinical Rheumatology 6/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.